These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms. Andersson KE Int J Clin Pract Suppl; 2006 Dec; (151):8-16. PubMed ID: 17169005 [TBL] [Abstract][Full Text] [Related]
6. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Chapple CR; Roehrborn CG Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611 [TBL] [Abstract][Full Text] [Related]
7. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Yamaguchi O Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275 [TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Drake MJ Expert Opin Emerg Drugs; 2008 Sep; 13(3):431-46. PubMed ID: 18764721 [TBL] [Abstract][Full Text] [Related]
9. Local effects of antimuscarinics. Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387 [TBL] [Abstract][Full Text] [Related]
10. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Hood B; Andersson KE Int J Urol; 2013 Jan; 20(1):21-7. PubMed ID: 23072271 [TBL] [Abstract][Full Text] [Related]
11. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M; Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951 [TBL] [Abstract][Full Text] [Related]
12. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424 [TBL] [Abstract][Full Text] [Related]
13. Developments in the pharmacotherapy of the overactive bladder. Sellers DJ; McKay N Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263 [TBL] [Abstract][Full Text] [Related]
14. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Thiagamoorthy G; Giarenis I; Cardozo L Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923 [TBL] [Abstract][Full Text] [Related]
17. Current and future pharmacotherapy for treating overactive bladder. Thiagamoorthy G; Cardozo L; Robinson D Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972 [TBL] [Abstract][Full Text] [Related]
18. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder. Andersson KE; Martin N; Nitti V J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471 [TBL] [Abstract][Full Text] [Related]
19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659 [TBL] [Abstract][Full Text] [Related]
20. The pharmacotherapy of overactive bladder. Athanasopoulos A Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]